Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for intervertebral body fusion in skeletally mature patients and is designed for use with autograft. The first iteration of the system launched in 3Q15, and was preceded by anterior lumbar and transforaminal lumbar versions.
Sources: Amedica Corporation, ORTHOWORLD Inc.
Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for...
Amedica received FDA 510(k) clearance for expanded sizes of the Valeo® II Lateral Lumbar silicon nitride interbody fusion device. Product launch will occur within the month, including second-generation instrumentation.
Valeo II LL is indicated for intervertebral body fusion in skeletally mature patients and is designed for use with autograft. The first iteration of the system launched in 3Q15, and was preceded by anterior lumbar and transforaminal lumbar versions.
Sources: Amedica Corporation, ORTHOWORLD Inc.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
